Max Kates, MD

Chetan Bettegowda is the director of the Johns Hopkins Department of Neurosurgery. He offers comprehensive treatments for adult patients with benign and malignant brain tumors, specializing in the treatment of patients with primary brain tumors such as gliomas, meningiomas and pituitary tumors. He performs both open surgery and stereotactic radiosurgery for patients with metastatic tumors to the brain, and also provides stereotactic radiosurgery for other neurological disorders, including spinal tumors, trigeminal neuralgia and skull-base tumors.

As the director of the Johns Hopkins Movement Disorders Division, Dr. Kelly Mills cares for patients who have movement disorders such as Parkinson’s disease, atypical parkinsonism, dystonia, ataxia, tremor and Huntington’s disease. He also evaluates and manages patients needing deep brain stimulation to manage their movement symptoms and provides botulinum toxin treatment for various disorders.In his research, Dr. Mills explores the cognitive dysfunction that can occur in movement disorders such as Parkinson’s disease. He is particularly interested in describing the role of the basal ganglia in cognition, especially in the context of various diseases that can affect this structure.His work focuses on clarifying how certain treatments might impact cognitive and psychiatric problems. For instance, Dr. Mills studies how deep brain stimulation, when used to treat movement symptoms, can impact cognitive function such as attention, memory or impulsivity.Dr. Mills is a Maryland native and a graduate of the University of Maryland School of Medicine, where he developed an interest in neurology and movement disorders.He trained at the University of California, San Francisco, where he completed his neurology residency as well as a clinical and research fellowship in movement disorders, with a particular emphasis on deep brain stimulation to treat Parkinson’s disease, tremor and dystonia.

Dr. Arthur Burnett is a professor of urology at the Johns Hopkins School of Medicine. He is the Patrick C. Walsh Professor of Urology. Dr. Burnett is the director of the Male Consultation Clinic at Johns Hopkins Hospital, a clinician-scientist at the James Buchanan Brady Urological Institute. Dr. Burnett is also Vice Chair for urology faculty development at the James Buchanan Brady Urological Institute Dr. Burnett received his undergraduate degree in biology from Princeton University and his medical degree at the Johns Hopkins University School of Medicine. He completed his internship and residency in surgery, and subsequently residency and fellowship in urology at The Johns Hopkins Hospital. Upon completion of his urology residency, he received an American Foundation of Urologic Disease New Investigator Award to continue research work into the regulatory mechanisms of penile erection. He has maintained an active laboratory in neurourology since that time. Dr. Burnett is an established expert in the areas of prostate cancer, lower genitourinary tract malignancies (penile, scrotal, and urethral cancers), lower genitourinary tract reconstruction (pelvic trauma and urethral stricture disease), erectile dysfunction and penile abnormalities (including Peyronies disease), and female urology (including urinary incontinence, urethral abnormalities, and prolapsed pelvic structures). He is an expert prostate cancer surgeon, having performed over 3,000 radical prostatectomies where he has proven his skill at applying a single, minimally invasive 3-inch incision just above the pubic bone to facilitate rapid recovery and cosmesis and using a nerve-sparing technique. He has also developed management approaches to improve postoperative functional outcomes following radical prostatectomy. Dr. Burnett is recognized for being a world-authority in the science and medicine of erectile dysfunction. He contributed original discoveries of the nitric oxide biochemical mechanisms in erectile tissue, which paved the way for the clinical development of oral medications to treat erectile dysfunction such as Viagra. He has also pioneered work to develop therapies to protect penile nerve function required for improved erectile function recovery after radical prostatectomy. Dr. Burnett has written more than 500 original peer-reviewed articles, along with numerous additional articles, editorials, and book chapters, and three books relating to his biomedical research and clinical activities. His work has appeared in many prominent journals such as Science, Nature Medicine, Proceedings of the National Academy of Sciences, New England Journal of Medicine, Journal of Urology, Urology, and Journal of Andrology. He has sat on various advisory committees including the Urology Study Section, National Institutes of Health Center for Scientific Review and FDA Advisory Committee for Reproductive Health Drugs. He also founded and directs a non-profit humanitarian organization called UroMissionsWorks Incorporated. He is an alumni member of the Alpha Omega Honor Medical Society and Fellow of the American College of Surgeons. Among various awards, Dr. Burnett received the Urology Care Foundation Distinguished Mentor Award in 2016, the Distinguished Contribution Award from the American Urological Association in 2018, the Ferdinand C. Valentine Medal from The New York Academy of Medicine in 2020, and the Hugh Hampton Young Award from the American Urological Association in 2022.